Elan

Top executives of Dublin-based over-the-counter drug company Perrigo arrived in Israel today for meetings with investors as they seek to fend off a ho(...)

Listed life sciences investment group Malin has reported its maiden set of results. Excluding the costs of establishing the company, Malin reported a (...)

Irish over-the-counter drug company Perrigo has filed a lawsuit against suitor Mylan in a Manhattan court. The legal action comes as Perrigo urged its(...)

Shareholders in over-the-counter drug specialists Perrigo receive their latest quarterly dividend today. It comes as they mull the formal offer for th(...)

Irish life sciences investment firm Malin completed its initial series of asset purchases with two more investments on Monday and said director and fo(...)

Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

AIB has committed €15 million to a dedicated life-sciences venture-capital fund managed by Dublin-based Fountain Healthcare Partners. AIB is investing(...)

Drugmaker Mylan offered to buy rival Perrigo for $28.9 billion in a deal that would create a powerhouse for generic medicine. Mylan, which makes abo(...)

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)